Role of Nefopam in Rituximab Transfusion Reaction

Ministry Of Health / Nineveh Health Directorate

Status and phase: Not yet enrolling; Phase 3

Conditions: Nefopam

Treatments: Drug: diphenhydramine ampule; Drug: Nefopam ampule

Study type: Interventional

Funder types: Other

Identifiers

NCT05648058

nefopam with rituximab

Details and patient eligibility

About

the patients will be taken nefopam ampule 50 mg before rituximab in the first group while the second group will be taken diphenhydramine ampule 10 mg before rituximab in the second group

Full description

the two groups will be taken standard therapy (hydrocortisone vial 100 mg and acetaminophen 1000 mg) 30 min before rituximab

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 - 80 years old male and female will be taken rituximab

Exclusion criteria

• less than 18 years old more than 80 years old diabetic patients

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

100 participants in 2 patient groups

nefopam

Experimental group

Description:

administration of intravenous nefopam to prevent Rituximab Transfusion Reaction

Treatment:

Drug: Nefopam ampule

diphenhydramine

Active Comparator group

Description:

administration of intravenous diphenhydramine to prevent Rituximab Transfusion Reaction

Treatment:

Drug: diphenhydramine ampule